Cancer vaccines in old age

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

Original languageEnglish (US)
Pages (from-to)441-450
Number of pages10
JournalExperimental Gerontology
Volume42
Issue number5 SPEC. ISS.
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Cancer Vaccines
T-cells
Vaccines
Chemotherapy
Poisons
Neoplasms
Active Immunotherapy
Radiation
Vaccination
T-Lymphocytes
Young Adult
Clinical Trials
Drug Therapy
Incidence
Population

Keywords

  • Aging
  • Breast cancer
  • Cancer vaccines
  • Immune system
  • Preclinical models

ASJC Scopus subject areas

  • Aging
  • Medicine(all)

Cite this

Cancer vaccines in old age. / Gravekamp, Claudia.

In: Experimental Gerontology, Vol. 42, No. 5 SPEC. ISS., 05.2007, p. 441-450.

Research output: Contribution to journalArticle

Gravekamp, Claudia. / Cancer vaccines in old age. In: Experimental Gerontology. 2007 ; Vol. 42, No. 5 SPEC. ISS. pp. 441-450.
@article{3982fce0ee0841f799bc73dab7cde53c,
title = "Cancer vaccines in old age",
abstract = "The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.",
keywords = "Aging, Breast cancer, Cancer vaccines, Immune system, Preclinical models",
author = "Claudia Gravekamp",
year = "2007",
month = "5",
doi = "10.1016/j.exger.2006.11.009",
language = "English (US)",
volume = "42",
pages = "441--450",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",
number = "5 SPEC. ISS.",

}

TY - JOUR

T1 - Cancer vaccines in old age

AU - Gravekamp, Claudia

PY - 2007/5

Y1 - 2007/5

N2 - The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

AB - The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

KW - Aging

KW - Breast cancer

KW - Cancer vaccines

KW - Immune system

KW - Preclinical models

UR - http://www.scopus.com/inward/record.url?scp=34147164486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147164486&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2006.11.009

DO - 10.1016/j.exger.2006.11.009

M3 - Article

C2 - 17197144

AN - SCOPUS:34147164486

VL - 42

SP - 441

EP - 450

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

IS - 5 SPEC. ISS.

ER -